Herein, we encountered an 89-year-old 
Introduction

The concept of colony stimulating factor (CSF) as a hematopoietic induction, differentiation, and growth factor was first discussed in 1966 (1). A case of malignancy was then later reported with increased CSF activation in serum and urine in 1974 (2). Afterwards, it was demonstrated for the first time that CSF was directly produced by a lung cancer tissue specimen in 1977 (3). Granulocyte-colony stimulating factor (G-CSF) is recognized as a naturally occurring glycoprotein that stimulates the proliferation and maturation of precursor cells in the bone marrow into fully differentiated neutrophils (4, 5). Although several accounts of G-CSF-producing malignant tumors in lung cancer exist, few have been observed in the digestive system. Notably, there have been very few cases found in pancreatic cancer; the 8 previous reports concerning G-CSF-producing pancreatic cancer are summarized in
.
Herein, we present only the second case of G-CSFproducing pancreatic adenosquamous carcinoma, which we were able to confirm by immunohistochemistry. (Fig. 4) g u l a r n a r r o wi n g o f t h e c o mmo n b i l e d u c t i n d u c e d b y e x t r i n s i c p r e s s u r e wa s s e e n  ( a r r o wh e a d s ) 
F i g u r e 1 . E n h a n c e d a b d o mi n a l c o mp u t e d t o mo g r a p h y s h o we d a p a r t o f t h e t u mo r wa s l o c a t e d f r o m t h e p a n c r e a t i c h e a d a n d u n c u s t o t h e p o r t a h e p a t i c a ( wh i t e c i r c l e ) . Mu l t i p l e me t a s t a t i c l e s i o n s i n t h e l i v e r p a r e n c h y ma we r e s i mu l t a n e o u s l y n o t i c e d ( n o t s h o wn ) .
f r o m t h e p o r t a h e p a t i c a t o t h e l o we r b i l e d u c t b y e n d o s c o p i c r e t r o g r a d e c h o l a n g i o g r a p h y . b ) E n d o s c o p i c r e t r o g r a d e p a n c r e a t o g r a p h y s h o we d o b s t r u c t i o n o f t h e ma i n p a n c r e a t i c d u c t ( a r r o wh e a d ) .
F i g u r e 5 . a ) Mi c r o s c o p i c f i n d i n g s s h o we d a t y p i c a l c e l l s l y i n g i n s h e e t s a n d c o mp o s e d o f a p o o r l y d i f f e r e n t i a t e d a d e n o s q u a mo u s c a r c i n o ma . He ma t o x y l i n a n d E o s i n s t a i n i n g , × 1 0 o r i g i n a l ma g n i f i c at i o n . b ) I mmu n o h i s t o c h e mi c a l e x a mi n a t i o n s h o we d p o s i t i v e s t a i n i n g f o r g r a n u l o c y t e -c o l o n y s t i mul a t i n g f a c t o r ( G-CS F ) i n t h e c y t o p l a s m a n d s u r f a c e o f t h e a t y p i c a l c e l l s ( a r r o wh e a d s ) . × 4 0 o r i g i n a l ma g n i f i c a t i o n . c ) Ne g a t i v e c o n t r o l . × 4 0 o r i g i n a l ma g n i f i c a t i o n . ness from massive ascites appeared, and she passed away on day 62. We later conducted a necropsy with informed consent from her family. The specimens taken from an ultrasound-guided tumor biopsy showed a poorlydifferentiated adenosquamous carcinoma with positive staining for G-CSF by immunohistochemistry (anti-G-CSF antibody, Calbiochem Ab-1, Darmstadt) (Fig. 5). Tissue specimens from concomitant gastric cancer were negative for G-CSF staining. We also tested for G-CSF receptor by immunostaining (anti-G-CSF receptor antibody, Abcam S-1284, Cambridge) but found no positive findings. Based on these results, she was diagnosed with G-CSF-producing pancreatic cancer.
Discussion
The immunological findings in our case are strongly indicative that the patient's pancreatic cancer produced G-CSF. Clinicians sometimes encounter leukocytosis of unknown origin in patients with advanced stage malignancies, and a number of these have been reported to be associated with a G-CSF-producing tumor. The diagnostic criteria for such a tumor are the following: 1) extreme leukocytosis, 2) elevated G-CSF activity, 3) fall-off of white blood cell count after tumor resection, or 4) proof of G-CSF production in the tumor (3). Both extreme leukocytosis and significant elevation of serum G-CSF were noticed in this patient. A reliable way to prove tumoral G-CSF production is by immunostaining (13). In our case, we directly proved by immunochemistry of pancreatic cancer tissue specimens taken at necropsy that the tumor had produced G-CSF. Since specimens taken from her concomitant gastric tumor showed the different tumor type of well-differentiated adenocarcinoma that was negative for G-CSF, we could confidently diagnose this patient with G-CSF-producing pancreatic cancer.
Most patients with pancreatic cancer experience pain, weight loss, or jaundice (14, 15) . Notably, pain is present in 80 to 85 percent of patients with locally advanced or advanced disease (14) . In addition, half of the 8 published cases of G-CSF-producing pancreatic cancer showed continuous fever without infective focus seen in this patient (Table 1) . Accordingly, such a symptom may be a clinical sign T a b l e 1 . P u b l i s h e d Ca s e s o f Gr a n u l o c y t e -c o l o n y S t i mu l a t i n g F a c t o r -p r o d u c i n g P a n c r e a t i c Ca n c e r of G-CSF-producing pancreatic cancer. IL-6 overproduction and high levels of serum CRP were also noticed in the present case, which may have been responsible for the fever. In a previous report, co-production of G-CSF and IL-6 was associated with IL-1 production in G-CSF-producing cancer cell lines (15) . IL-6 is considered to act as an endogenous pyrogen (16, 17) that regulates the synthesis of acute phase proteins, including CRP (18, 19 (20) . The median survival rates in patients undergoing radical resection for this disease are from 11.5 to 26 months (21, 22) , and the median survival time for patients receiving gemcitabine chemotherapy is 5.65 months (23) . In addition, the prognosis of G-CSF-producing tumors is generally considered to be poor (24) (25) , and G-CSF was also considered to be a major autocrine growth factor in rapid tumor proliferation and metastasis (26, 27 
